middle.news
Racura Oncology Taps Beyond Drug Development for Pivotal Lung Cancer Trial
9:33am on Wednesday 24th of December, 2025 AEDT
•
Healthcare
Read Story
Racura Oncology Taps Beyond Drug Development for Pivotal Lung Cancer Trial
9:33am on Wednesday 24th of December, 2025 AEDT
Key Points
Beyond Drug Development appointed as CRO for HARNESS-1 trial
Phase 1a/b study to recruit up to 80 EGFR-mutated NSCLC patients across five Australian sites
Trial to assess safety, dosage, pharmacokinetics, and preliminary efficacy of RC220 plus osimertinib
Contract valued at approximately AUD 3.05 million with milestone-based payments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE